PSA

Timing of PSA Nadir Post-RP Predicts Biochemical Recurrence Risk

Timing of PSA Nadir Post-RP Predicts Biochemical Recurrence Risk

By

A detectable PSA nadir combined with shorter time to nadir after prostate cancer surgery is associated with a higher risk of biochemical recurrence.

PSA Testing in Controls of Screening Trial May Undermine Results

PSA Testing in Controls of Screening Trial May Undermine Results

Over 15 years of follow-up, considerable proportion of men undergo prostate-specific antigen testing

Low-PSA, High-Grade Prostate Cancer Especially Lethal

Low-PSA, High-Grade Prostate Cancer Especially Lethal

By

Men with PSA values of 2.5 ng/mL or less and Gleason 8 to 10 prostate tumors are at higher risk of death than other high-risk PCa patients.

Novel PSA Assay Improves Prostate Cancer Diagnosis

Novel PSA Assay Improves Prostate Cancer Diagnosis

By

The new test, IsoPSA, measures all PSA isoforms in serum and more accurately discriminates high-grade cancer from benign disease.

PSA Surge With Abiraterone Has No Long-Term Impact on Outcome

PSA Surge With Abiraterone Has No Long-Term Impact on Outcome

By

Spike in PSA level after starting abiraterone does not affect progression-free or overall survival, study finds.

More Preclinical PCa, Progression Among Black Men

More Preclinical PCa, Progression Among Black Men

Also increased risk of progression to metastatic disease compared with the general population.

USPSTF Issues Draft PCa Screening Recommendations

USPSTF Issues Draft PCa Screening Recommendations

By

The US Preventive Services Task Force now suggests decisions about PSA testing should be made on an individual basis for men aged 55 to 69.

Earlier vs Later Prostate Cancer Recurrence Characterized

Earlier vs Later Prostate Cancer Recurrence Characterized

By

Pathologic Gleason scores, positive surgical margin rates, and PSA doubling times differentiate earlier from later biochemical recurrence after radical surgery.

Many Men Lack Information on PSA Screening Pros, Cons

Many Men Lack Information on PSA Screening Pros, Cons

By

In 2014, 33.9% of men reported that their health care providers failed to communicate the benefits and risks of PSA-based screening, an increase from 2012.

PSA, PSAD Less Predictive of Aggressive PCa in Black Men

PSA, PSAD Less Predictive of Aggressive PCa in Black Men

By

Study finds that PSA and PSAD indicated prostate cancer above Gleason score 6 for white men only.

5-Year PCa-Specific Mortality Declined With Increased PSA Testing

5-Year PCa-Specific Mortality Declined With Increased PSA Testing

By

From 1995 to 2011, prostate cancer deaths fell by 13.0% among Danish patients diagnosed with low-risk disease.

Black Patients May Be Adversely Affected by Less PSA Screening

Black Patients May Be Adversely Affected by Less PSA Screening

By

Black patients who met age criteria for PSA screening were 28% more likely to die of their prostate cancer than patients ineligible for screening.

Fewer Prostate Biopsies After USPSTF Limited PSA Screening

Fewer Prostate Biopsies After USPSTF Limited PSA Screening

Following the 2012 USPSTF recommendation against PSA screening in populations, rates of radical prostatectomy and biopsy have become significantly less common.

New Prostate Cancer Screening Algorithm Proposed

New Prostate Cancer Screening Algorithm Proposed

By

A PSA level of 1.5 ng/mL or higher should prompt primary care physicians to refer patients to a urologist for further evaluation.

Radiographic Progression of mCRPC Without Rising PSA

Radiographic Progression of mCRPC Without Rising PSA

By

In a PREVAIL trial post hoc analysis, nearly one fourth of men on enzalutamide had radiographic progression despite non-rising PSA.

PCa Deaths Rare Among Men With Benign 1st Biopsy and Low PSA

PCa Deaths Rare Among Men With Benign 1st Biopsy and Low PSA

By

After 20 years, the prostate cancer mortality rate was 0.7% for men with a PSA level of 10 ng/mL or less and benign initial biopsy results.

Digital Rectal Examination, PSA Testing Rates Declining

Digital Rectal Examination, PSA Testing Rates Declining

Decreases in use of screening following USPSTF recommendations against routine PSA screening.

Latest Assays Can Improve Prostate Cancer Workup

Latest Assays Can Improve Prostate Cancer Workup

Clinicians now have tools for improving prostate cancer screening and risk stratification.

PSA of ≥0.4 ng/mL Predicts PCa Progression

PSA of ≥0.4 ng/mL Predicts PCa Progression

Shows the strongest correlation between biochemical recurrence and subsequent systemic progression.

Midlife PSA Levels Predict Lethal Prostate Cancer

Midlife PSA Levels Predict Lethal Prostate Cancer

By

The odds of developing lethal prostate cancer were increased by 6.9 to 12.6 times for men aged 40 to 59 years with higher PSA values.

High PSA Predicts Elevated Risk of Lower Urinary Tract  Symptoms

High PSA Predicts Elevated Risk of Lower Urinary Tract Symptoms

By

LUTS is 49% more likely to develop in men with a PSA level above 6 ng/mL versus 4 ng/mL or less.

Landmark PSA Screening Trial Results Challenged

Landmark PSA Screening Trial Results Challenged

By

The PLCO trial's conclusion that routine PSA testing does not affect prostate cancer mortality risk could be wrong.

PSA Screening More Likely Among Blacks

PSA Screening More Likely Among Blacks

The odds of PSA screening were higher among blacks than non-Hispanic whites.

Fluoroquinolones May Be Unwarranted for High PSA

Fluoroquinolones May Be Unwarranted for High PSA

By

PSA level declined by an average of 0.68 ng/mL in the treatment group.

Clinician Training Influences PSA Screening in Senior Veterans

Clinician Training Influences PSA Screening in Senior Veterans

Older men whose clinician was a physician trainee had substantially lower prostate-specific antigen (PSA) screening rates.

Prostate Biopsy Rates Fall Following Guideline Updates

Prostate Biopsy Rates Fall Following Guideline Updates

By

The proportion of biopsied men who have complications from the procedure rose from 14% to 18% from 2005 to 2014.

Only Conservative PSA Testing is Cost-Effective

Only Conservative PSA Testing is Cost-Effective

This includes less frequent screening and more restrictive biopsy referral criteria.

Impact of USPSTF Rec Against PSA Screening Varied for Urologists, PCPs

Impact of USPSTF Rec Against PSA Screening Varied for Urologists, PCPs

Differential effect of 2012 USPSTF recommendations for primary care providers, urologists.

Many Seniors Have Non-Recommended PSA Screening

Many Seniors Have Non-Recommended PSA Screening

Rate of unnecessary screening was 15.7% in men 65 years and older.

Lower PSA Thresholds Predict Increased PCa Risk in Veterans

Lower PSA Thresholds Predict Increased PCa Risk in Veterans

By

Prostate cancer is 1.4 times more likely to develop in those with a PSA level of 2.5 ng/mL or higher.

Sign Up for Free e-newsletters